» Therapeutic options

Medical therapy for endometriosis in adolescents prioritizes pain relief, suppression of disease progression, and protection of future fertility. Progestogens and combined oral contraceptives are the first-line treatments, used continuously rather than cyclically to maximize effectiveness. If symptoms persist after four months of continuous therapy, a surgical approach may be considered. GnRH agonists, combined with hormonal ‘add-back therapy,’ are a second-line option for those not responding to initial treatments.

The choice of therapy should be tailored to individual needs, taking into account factors like efficacy, safety, tolerability, and route of administration. Compliance and regular follow-ups are essential for monitoring therapy effectiveness and disease progression. For persistent or severe symptoms, long-term treatment is necessary, and alternative administration routes (oral, transdermal, vaginal) may be considered to improve patient comfort and adherence.

Reading time : 3 minutes

First-Line Treatments: Hormonal Therapy

The cornerstone of medical therapy for endometriosis in adolescents is hormonal treatment. This approach aims to manage pain, suppress disease progression, and protect fertility. The primary options include:

Progestogens: These hormones are often used as a first-line treatment for endometriosis. Progestogens work by inducing a hypoestrogenic state, reducing inflammation, and limiting the growth of endometrial tissue. They are available in various forms, including oral tablets, injections, and intrauterine devices (IUDs).
Combined Oral Contraceptives (COCs): COCs combine estrogen and progestin and are widely used to manage endometriosis-related pain. They are often prescribed in a continuous regimen to suppress menstruation and reduce the recurrence of symptoms.

Both progestogens and COCs are recommended as first-line treatments by the European Society of Human Reproduction and Embryology (ESHRE) and other major guidelines. The choice between these options often depends on the patient’s individual preferences, tolerability, and specific symptoms.

Second-Line Treatments: GnRH Agonists

When first-line treatments fail to provide adequate relief, GnRH (Gonadotropin-Releasing Hormone) agonists may be considered. These medications suppress ovarian hormone production, creating a temporary menopausal state that reduces endometriosis symptoms. However, due to their significant side effects, such as bone density loss and menopausal symptoms, GnRH agonists are generally used with "add-back" therapy to mitigate these effects and are considered a second-line option.

Tailoring Treatment to the Adolescent Patient

One of the key principles in managing endometriosis in adolescents is the need for tailored treatment. There is no one-size-fits-all approach, and therapy must be adjusted based on several factors:

Efficacy: The effectiveness of the treatment in relieving symptoms.
Safety and Adverse Effects: Potential side effects must be weighed, particularly in young patients who may be more vulnerable to long-term consequences like bone density loss.
Tolerability: The patient’s ability to tolerate the treatment, both physically and psychologically.
Route of Administration: Options include oral, transdermal (patch), vaginal ring, and long-acting reversible contraceptives (LARCs), each with its own set of advantages and considerations.

Clinicians are encouraged to involve adolescents in the decision-making process, ensuring that they understand the benefits and risks of each option. This approach fosters better compliance and outcomes.

Continuous vs. Cyclical Regimens

For many adolescents, continuous administration of hormonal therapy is preferred over cyclical use. Continuous regimens, which avoid the hormonal fluctuations associated with the menstrual cycle, have been shown to be more effective in managing symptoms such as dysmenorrhea and chronic pelvic pain. Studies suggest that continuous use of hormonal therapy can lead to significant improvements in quality of life, with fewer breakthrough symptoms compared to cyclical use.

Considerations for Long-Term Management

Endometriosis is a chronic condition, and long-term management strategies are crucial. For adolescents, this often involves extended use of hormonal therapy to maintain symptom control and prevent recurrence. Regular follow-ups are essential to monitor the effectiveness of the treatment, adjust dosages as needed, and address any side effects.

Moreover, the impact of long-term hormonal therapy on bone health is a particular concern in adolescents. While therapies like GnRH agonists can affect bone mineral density, options such as LARCs and progestogen-only treatments are generally safer for prolonged use.

Conclusion

Managing endometriosis in adolescents requires a comprehensive, individualized approach that prioritizes both immediate symptom relief and long-term health outcomes. Hormonal therapies, including progestogens and combined oral contraceptives, remain the first-line treatments, with GnRH agonists reserved for cases where these are ineffective. By tailoring treatment to the unique needs of each patient, clinicians can help young women manage their symptoms effectively and improve their quality of life, ensuring a healthier future.